The 2021 Global Generics & Biosimilars Awards winners by category:
Milan, 11 November, 2021: The Global Generics & Biosimilars Awards winners have now been announced at last night’s Awards ceremony, which took place in Milan, Italy. Stretching across 14 categories, the Awards recognize achievements across the global off-patent industry, including breakthroughs in small-molecule generics, biosimilars and value-added medicines; as well as celebrating the industry’s biggest deals, regulatory milestones and company leaders.
The Award for Corporate Social Responsibility (CSR) Initiative of the Year was given to Dr. Reddy's Laboratories, for their “excellent, well rounded CSR programme with tangible KPIs and outcomes, which went beyond the immediate need of COVID-19 to support vulnerable communities in the long term”.
Regulatory Achievement of the Year was awarded to Sandoz, for what the judges described as being “excellent work to assist a typically, under-privileged part of society in managing a horrible disease.”
The Biosimilar Initiative of the Year award went to Celltrion Healthcare, who have been regarded as a ‘first-mover’ in the biopharmaceutical industry following development of the world’s first antibody biosimilar, Remsima.
Dr. Reddy's Laboratories’ API Team came out top for API Supplier of the Year after having showed a strong commitment as a reliable API supplier to global formulating companies but also to taking on the challenge of being part of the solution to address the pandemic. Our judges said that Dr Reddy’s had demonstrated “great flexibility during the crisis’ tremendous market expansion.”
The Award for Industry Partner of the Year went to Rephine after they had to adapt their service offering and develop solutions to continue to support partners within the industry during the global pandemic.
This year’s Business Development of the Year Award went to Accord Healthcare. Our judges recognized Accord for the firm’s “100 plus commercialised INNs, three biosimilars and innovative products such as long-acting depots & implants” which demonstrated “clear BD excellence.”
Celltrion Healthcare came up trumps again as they also won Value Added Medicine Initiative of the Year.
Acquisition of the Year went to Sandoz as early this year they announced an agreement to acquire GSK’s global cephalosporin antibiotics business. Our judges said the deal “not only fits perfectly with Sandoz's existing footprint and strategy but also plays into the wider theme of improving Europe's self-sufficiency in key medicines.”
This year’s Award for Intellectual Property Strategy of the Year went to Unipharm. The case involved clopidogrel – a drug sold by Sanofi, which had been able to increase its monopoly term by avoiding disclosing critical information regarding the patent.
Congratulations to 2021’s Leader of the Year, Anil Okay, General Manager at Adalvo. Anil has over 15 years of professional working experience in the industry with an impressive track record as an experienced international leader managing over 100 headcounts spread in more than 20 countries worldwide. He set up the Adalvo business in its entirety, and has been the driver of the company's impressive and fast growth.
Eurofarma Laboratórios excelled in the Company of the Year, Americas category. Our judges highlighted “Eurofarma’s achievements include signing a partnership to be a manufacturer of Pfizer's COVID-19 vaccine for Latin America.”
Company of the Year, Asia-Pacific saw Beximco Pharmaceuticals take home the trophy after they achieved double-digit growth, attained excellent profit growth, enriched its product portfolio, won global awards for their COVID-19 response, and delivered excellent results for shareholders.
The trophy for Company of the Year, EMEA went to Stada for leading the way in Europe's generics, biosimilars, value-added and consumer healthcare industries in terms of financial performance, targeted acquisitions, business-development deals and CSR sustainability activities.
Finally, the award for global Company of the Year was handed to Celltrion Healthcare which meant they took home a hattrick in Awards last night. Celltrion started in 2002 as a small biopharma company based in South Korea. Over the past twenty years it has grown to become a leading global biopharmaceutical company with an evolved vision: to transform from a ‘first mover’ to a ‘game changer’ by 2030.
David Wallace, Executive Editor, Generics Bulletin, added: “What a fantastic evening and what a remarkable year we have had for generics and biosimilars. It was truly great to be able to celebrate and acknowledge the achievements made by the off-patent industry in delivering high-quality medicines to those around the globe who need them most. And it was extra special to be able to hold the event in-person again after such a turbulent year.
We received a fantastic standard of entries and this year’s winners are extremely worthy.
I would like to thank everyone that entered this year, along with our sponsors, nominees and judges, and offer my sincere congratulations to this year’s winners.”
For more information visit pharmaintelligence.informa.com.
About the Global Generics & Biosimilars Awards
The Global Generics & Biosimilars Awards is the one night of the year when the off-patent pharmaceutical industry’s greatest achievements are put in the spotlight.
Taking place on November 10, 2021 at the Stella Polare, Fiera Milano, Milan, Italy, the Global Generics & Biosimilars Awards 2021 recognized companies across the off-patent industry, including small-molecule generics, biosimilars and value-added medicines, by celebrating their successes over the past year.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: